What should I pay attention to when getting the Haemophilus influenzae type b vaccine

Nowadays, there are many vaccines that actually require us to pay attention to their effects and to carry out the injections carefully according to the doctor's instructions. Among them, the Haemophilus influenzae type b vaccine is one of the vaccines that requires further injection in a regular hospital. Haemophilus influenzae type b vaccine, as the name suggests, is a vaccine used to prevent influenza. So what are the precautions for the Haemophilus influenzae type b vaccine?

In a multicenter clinical study (n=903) comparing the efficacy of this product and freeze-dried Haemophilus influenzae type b vaccine, 678 healthy American infants and toddlers aged 2-6 months received 1,699 doses of this product. Most of the recipients also received DPT (diphtheria, pertussis and tetanus) and OPV (oral polio vaccine) at the same time. The recipients tolerated the two different dosage forms of Haemophilus influenzae type b vaccine well, and no serious vaccine-related adverse reactions were found.

Within three days after the first vaccination of this product, the most common adverse reactions (incidence > 1%, regardless of the cause, except those listed in Table 1) are, in descending order of incidence: irritability, drowsiness, pain at the injection site, erythema at the injection site (diameter ≤ 2.5 cm, see Table 1), mass/nodule at the injection site (diameter ≤ 2.5 cm, see Table 1), abnormally loud crying, prolonged crying (> 4 hours), diarrhea, vomiting, crying, pain, otitis media, rash and upper respiratory tract infection.

After the infants and young children received the first vaccination with this product, their parents were observed for more than 48 hours, and the selected objective observation indicators reported were listed in Table 1.

The types and incidence of adverse reactions observed within 3 days after booster vaccination were similar to those after primary vaccination.

Post-marketing experience

Like any vaccine, some adverse reactions that were not found in clinical studies may be discovered after widespread clinical use of this product. The following adverse reactions have been reported:

Blood and lymphatic system

Lymphadenopathy

Allergies

Rare angioedema

Nervous system

Seizures (including febrile seizures)

skin

Ulcers at sterile injection sites; pain at injection sites.

Precautions

Patients with malignant tumors, patients receiving immunosuppressive treatment, or those with other immune deficiencies may not be able to obtain the expected immune protection effect if vaccinated with this product.

If an allergic reaction occurs after vaccination with this product, effective treatment measures should be taken promptly, and adrenaline and other drugs can be used for first aid if necessary.

As with other vaccines, this product may not induce the body to produce protective levels of antibodies immediately after vaccination.

Like other vaccines, not 100% of the vaccinated subjects will produce a protective antibody response after vaccination with this product.

Similar to what has been reported with the Haemophilus influenzae type b polysaccharide vaccine and another Haemophilus influenzae type b conjugate vaccine, disease caused by Haemophilus influenzae type b may occur within one week of vaccination with this product before the body induces a protective effect against the bacteria.

There is insufficient evidence to show whether vaccination with this medicine promptly after natural exposure to Haemophilus influenzae type b can prevent the onset of disease.

Vaccination with this drug should be postponed during any acute infection or febrile illness unless the doctor believes that not getting the vaccine will result in a more serious danger.

After vaccination with this product, an immunogenic response to the carrier protein (meningococcus) will be produced, but the clinical significance of this response is unclear.

In addition, there is a very important note when injecting the Haemophilus influenzae type b vaccine, that is, if a person is confirmed to be allergic to any component of the Haemophilus influenzae type b vaccine, he or she should not use the Haemophilus influenzae type b vaccine. It is recommended that children aged 6 years and over be vaccinated with Haemophilus influenzae type b vaccine.